Some types of cancers show mutations in their EGFRs, which may cause unregulated cell division through continual or abnormal activation of the EGFR. EGFR inhibitors can be classified as either: tyrosine kinase inhibitors (TKI) (eg, erlotinib, gefitinib): these bind to the tyrosine kinase ...
Differentially expressed gene lists can be extracted from RNA-seq or microarray studies; gene lists can be created from genes harboring mutations in cohorts of patients, or gene lists can be putative targets of transcription factors or histone modifications profiled by ChIP-seq. In fact, gene ...
Differentially expressed gene lists can be extracted from RNA-seq or microarray studies; gene lists can be created from genes harboring mutations in cohorts of patients, or gene lists can be putative targets of transcription factors or histone modifications profiled by ChIP-seq. In fact, gene ...
aMutations in EGFR—either small in-frame deletions in exon 19 or aminoacid substitution clustered around the ATP-binding pocket of the tyrosine kinase domain—are present in 10–26% of non-small-cell lung cancer (NSCLC)tumours and are associated with response to gefi tinib and erlotinib. 变...
IMFINZI, in combination with tremelimumab-actl and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Small Cell Lung Cancer...
EGFR Mutation Test v2 P120019S007 Roche Molecular Systems, Inc. (NSCLC) patients. The test is intended to aid in identifying patients with NSCLC whose tumors have defined EGFR mutations and for whom safety and efficacy of a drug have been established as follows: Tarceva? (erlotinib) - Exon ...
FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. ONCOTARGET https://dx.doi.org/10.18632/oncotarget.13790 Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. SCIENTIFIC REPORTS...
The MAPK pathway is activated in approximately 30% of all human cancers via RAS-, BRAF-, or MAP2K1 (MEK1)-activating mutations. In addition, alterations known to activate the MAPK pathway are also common in acquired resistance to BRAF, MEK, ALK, CDK4/6, TRKA, and EGFR inhibitors. ...
Hypoxia-induced pulmonary vasoconstriction in patients with a medical history of high-altitude pulmonary edema (HAPE) may involve activation of the endothe... I Pham,G Wuerzner,JP Richalet,... - 《Pulmonary Circulation》 被引量: 25发表: 2012年 TP53, STK11 and EGFR Mutations Predict Tumor ...
(2:1), active-controlled trial in patients with previously untreated, metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. A total of 607 patients received ALIMTA, pembrolizumab, and platinum every 3 weeks for 4 cycles followed by ALIMTA and pembrolizumab (n=405), or ...